Top Markets
#1 Black Phoenix Black Phoenix +355.18%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.04%
#4 Akedo Akedo +53.98%
#5 Acurast Acurast +32.15%
#6 BasedHype BasedHype +28.07%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +18.15%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.84%
#10 HOME HOME +14.70%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Sigyn Therapeutics, Inc. Sigyn Therapeutics, Inc.

Sigyn Therapeutics, Inc.

SIGY
Clasificación en acciones #41048
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise... Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. The company is headquartered in San Diego, California.
Precio por acción
$0.03
Última sincronización: 2026-08-12
Capitalización bursátil
$48.16K
Cambio (1 día)
-23.08%
Cambio (1 año)
-98.93%
País
US
Comercio Sigyn Therapeutics, Inc. (SIGY)

Categoría

Healthcare
Ganancias de Sigyn Therapeutics, Inc. (SIGY)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Sigyn Therapeutics, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Sigyn Therapeutics, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE